OncoSec Medical, Inc. (OTC:ONCS) keeps climbing up. The up move started on Tuesday and continued yesterday, when the 
stock added the next 16.47% to its price. Along with the price jump, traded volume of ONCS reached 3.8 million shares for the day. Nevertheless, no reasonable explanation on the massive trade can be found.
The last press release by OncoSec came up on April 10, when the company reported that members of its executive team have contributed an article for Manufacturing Chemist reviewing current strategies for treatment of solid tumors. Additionally, a feature was written in the April 9 edition of the San Diego Business Journal.
The articles on the approaches to tumor treatment gave new hopes to investors, though these failed to pump up ONCS stock price. Presently, there is no news on OncoSec, however, the stock is moving up.
OncoSec Medical Inc. is an advanced-stage biomedical company focused on commercializing therapeutic oncology products. Last month, ONCS stock price got supported by some pump mails and more positive publications, though the gain was shortly broken.
In March, this year, Oncosec has entered into a couple of Purchase Agreements for the issuance and sale of certain amount of shares of the company’s common stock and warrants. However, the quarterly report of ONCS looks discouraging.
As of January 31, 2012 the company’s total assets were approximately 50% lower than its liabilities, while the revenue kept missing. Meanwhile, the stockholders’ deficit totaled over $2 million, and the deficit accumulated during the development stage period kept pointing more than $3 million.[BANNER]
The management state that as of January 31, ONCS has had cash and cash equivalents of $456,242 and they do not expect these funds to be sufficient to operate their business through July 31, 2012. Thus, the company will require additional financing to fund its operations, including commercializing any assets obtained under the Asset Purchase Agreement and meeting its obligations to Inovio, which require further payments to make.
However, if OncoSec obtains additional financing by issuing equity securities, its existing stockholders’ ownership will be diluted. Also, if obtaining commercial loans, these will increase the company’s liabilities and future cash commitments and investors may be unable to obtain a return on their investments in ONCS common stock.
